In glioma, over 80% of WHO grade II/III patients exhibit IDH mutations, while in WHO grade IV GBM, IDH mutations are prevalent in secondary GBM (73%) but rare in primary GBM (3.7%) (64, 65). This evidence concerns the gene IDH1 and central nervous system cancer.